Vietnam Enterprise Investment and Development JSC (HNX:FID)

Verve Therapeutics Cash Flow Statement

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Jan 1, 2024	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	308.02	4,357	-11,041	63.61	978.62	-2,004
Depreciation & Amortization	15,449	11,526	9,407	3,048	3,048	-
Loss (Gain) From Sale of Assets	-60.48	-	-	-	-	-
Other Operating Activities	-11,279	-13,278	2,357	-15.14	-1,017	1,963
Change in Accounts Receivable	9,834	12,156	-4,720	-312.47	-8,353	66,030
Change in Inventory	-	-	157.94	246.94	-	-182.82
Change in Accounts Payable	9,132	6,611	5,042	-4,438	-4,254	-87,452
Change in Other Net Operating Assets	299.67	239.73	227.08	-609.98	-	-
Operating Cash Flow	23,683	21,611	1,430	-2,016	-9,597	-21,645
Operating Cash Flow Growth	6311.77%	1411.47%	-	-	-	-
Investment in Securities	-22,000	-	812.46	-	-	21,650
Other Investing Activities	60.71	0.18	322.25	1.11	1.41	0.04
Investing Cash Flow	-21,939	-2,000	1,135	1.11	1.41	21,650
Long-Term Debt Repaid	-	-	-2,100	-	-	-
Net Debt Issued (Repaid)	-	-	-2,100	-	-	-
Issuance of Common Stock	-	-	-	-	11,760	-
Financing Cash Flow	-	-	-2,100	-	11,760	-
Net Cash Flow	1,744	19,611	464.52	-2,015	2,165	5.21
Free Cash Flow	23,683	21,611	1,430	-2,016	-9,597	-21,645
Free Cash Flow Growth	6311.77%	1411.47%	-	-	-	-
Free Cash Flow Margin	31.73%	38.50%	1.70%	-5.26%	-6.84%	-26.30%
Free Cash Flow Per Share	958.17	874.38	57.85	-95.09	-392.25	-918.29
Cash Income Tax Paid	-	-	32.12	46.15	8.46	97.78
Levered Free Cash Flow	83,060	17,199	44,246	-1,380	-9,539	756.78
Unlevered Free Cash Flow	87,133	20,471	46,886	-1,380	-9,539	2,037
Change in Net Working Capital	-63,774	104.08	-55,071	4,517	12,572	-2,000

Source: S&P Global Market Intelligence. Standard template. Financial Sources.